TABLE 6.
MM model-informed individualized initial dose regimens based on simulation.
| CYP3A5 genotype | With TAF co-therapy | Without TAF co-therapy | ||||
|---|---|---|---|---|---|---|
| HCT 20%–30% | HCT 30%–40% | HCT 40%–50% | HCT 20%–30% | HCT 30%–40% | HCT 40%–50% | |
| CYP3A5*1/*1 or CYP3A5*1/*3 | ||||||
| TBIL<17.1 μmol L−1 | 3.25–4 mg | 2.75–3.25 mg | 2.25–3 mg | 5–5.5 mg | 4.5–5 mg | 4–4.5 mg |
| 17.1 ≤ TBIL<85.5 μmol L−1 | 2.5–3.25 mg | 2–2.75 mg | 1.75–2.25 mg | 4.5–5 mg | 3.75–4.5 mg | 3.25–4 mg |
| 85.5 ≤ TBIL<171 μmol L−1 | 2.25–3 mg | 1.75–2.25 mg | 1.5–2 mg | 4–4.5 mg | 3.5–4 mg | 3–3.5 mg |
| TBIL≥171 μmol L−1 | 2–2.5 mg | 1.5–2 mg | 1.25–1.75 mg | 3.75–4.25 mg | 3.25–3.75 mg | 2.75–3.25 mg |
| CYP3A5*3/*3 | ||||||
| TBIL<17.1 μmol L−1 | 2.5–3.25 mg | 2–2.5 mg | 1.75–2.25 mg | 4.5–5 mg | 3.75–4.5 mg | 3.25–4 mg |
| 17.1 ≤ TBIL<85.5 μmol L−1 | 2–2.5 mg | 1.5–2 mg | 1.25–1.75 mg | 3.75–4.25 mg | 3–3.75 mg | 2.5–3.25 mg |
| 85.5 ≤ TBIL<171 μmol L−1 | 1.75–2.25 mg | 1.25–1.75 mg | 1–1.5 mg | 3.25–4.25 mg | 2.75–3.75 mg | 2.25–3.25 mg |
| TBIL≥171 μmol L−1 | 1.5–2 mg | 1.25–1.5 mg | 1–1.25 mg | 3–3.75 mg | 2.5–3 mg | 2–2.5 mg |